Novo Nordisk rebrands as "Novo" under it's "Lasting health starts now" tagline, pairing both with a new cultural framework called "The Novo Way."
|Articles|June 20, 2017
Myeloma UK Announces New CEO
Advertisement
Myeloma UK announced that Rosemarie Finley has been appointed its new CEO. She is joining the company from the Epilepsy Society, where she was Acting Chief Executive and Chief Operating Officer.
Finley has held positions at Buckinghamshire Healthcare NHS Trust and has worked as a strategic advisor to several pharmaceutical companies, gaining over 30 years of management experience in the healthcare sector.
Myeloma UK is the primary organization in the UK dealing with myeloma, a type of blood cancer that affects plasma cells in the bone marrow. Its focus is on unlocking the potential for the development and delivery of new treatments, through primary research, strategic partnerships, education, and campaigning.
Advertisement
Related to this article
AbbVie partners with Iambic on AI-driven drug discovery as Telix Pharmaceuticals moves to acquire ITM Isotope Technologies in a multibillion-dollar radiopharmaceutical merger, Novo Nordisk's CagriSema outperforms Eli Lilly's tirzepatide in a head-to-head diabetes trial, and Jen Lamppa of Inovalon discusses how real-time clinical data is reshaping trial recruitment.
AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.
Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses.
Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Advertisement
Advertisement
Trending on PharmExec
1
CagriSema Tops Eli Lilly's Tirzepatide for Weight Loss in Late-Stage Diabetes Trial: Report
2
Roundup: AbbVie & Iambic Enter Ai Drug Discovery Collaboration, Telix Merges with ITM
3
Understanding the Latest with MFN Pricing and What It Means to Pharma
4
The Battle to Own the GLP-1 Patient Journey
5